全文获取类型
收费全文 | 1684561篇 |
免费 | 139756篇 |
国内免费 | 2893篇 |
专业分类
耳鼻咽喉 | 22623篇 |
儿科学 | 55062篇 |
妇产科学 | 47608篇 |
基础医学 | 239812篇 |
口腔科学 | 49141篇 |
临床医学 | 149734篇 |
内科学 | 332343篇 |
皮肤病学 | 35649篇 |
神经病学 | 139305篇 |
特种医学 | 68106篇 |
外国民族医学 | 479篇 |
外科学 | 255803篇 |
综合类 | 40732篇 |
现状与发展 | 3篇 |
一般理论 | 606篇 |
预防医学 | 129695篇 |
眼科学 | 37928篇 |
药学 | 126842篇 |
3篇 | |
中国医学 | 3069篇 |
肿瘤学 | 92667篇 |
出版年
2018年 | 16838篇 |
2016年 | 14732篇 |
2015年 | 17144篇 |
2014年 | 23420篇 |
2013年 | 35047篇 |
2012年 | 48240篇 |
2011年 | 50465篇 |
2010年 | 29741篇 |
2009年 | 28456篇 |
2008年 | 48008篇 |
2007年 | 50752篇 |
2006年 | 51187篇 |
2005年 | 49717篇 |
2004年 | 48812篇 |
2003年 | 46398篇 |
2002年 | 45470篇 |
2001年 | 77065篇 |
2000年 | 79607篇 |
1999年 | 67638篇 |
1998年 | 18744篇 |
1997年 | 17128篇 |
1996年 | 16962篇 |
1995年 | 16684篇 |
1994年 | 15636篇 |
1993年 | 14724篇 |
1992年 | 56182篇 |
1991年 | 54485篇 |
1990年 | 53234篇 |
1989年 | 51444篇 |
1988年 | 47779篇 |
1987年 | 47112篇 |
1986年 | 44839篇 |
1985年 | 43440篇 |
1984年 | 32505篇 |
1983年 | 27956篇 |
1982年 | 16565篇 |
1981年 | 14774篇 |
1980年 | 13848篇 |
1979年 | 30815篇 |
1978年 | 21358篇 |
1977年 | 18034篇 |
1976年 | 16902篇 |
1975年 | 17833篇 |
1974年 | 21745篇 |
1973年 | 20930篇 |
1972年 | 19080篇 |
1971年 | 17942篇 |
1970年 | 16484篇 |
1969年 | 15461篇 |
1968年 | 14092篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Martin F. Shapiro 《Journal of general internal medicine》2015,30(10):1392-1393
82.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
83.
Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study 下载免费PDF全文
84.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
85.
86.
87.
88.
89.
90.